Xiangxue Pharmaceutical has raised CNY500m ($75.56m) through the second tranche of a public offering of corporate bonds.

The company secured CNY600m ($90.23m) through the first tranche of a public offering of its corporate bonds in October.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The latest offering brings the value of total issued bonds to CNY1.2bn ($181m), which includes CNY300m ($45.3m) through a public offering and CNY200m ($30.2m) through over allotment.

AstraZeneca has partnered with Chinese Future Industry Investment Fund (FIIF) to form a joint venture (JV) named Dizal Pharmaceutical.

The JV, which will be based in China, will integrate AstraZeneca Innovation Center China’s scientific and technical capabilities with FIIF’s funding and expertise in establishing strategic partnerships.

Astrazeneca and FIIF aim to strengthen drug discovery and development for patients through the JV.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“AstraZeneca has partnered with Chinese Future Industry Investment Fund (FIIF) to form a joint venture (JV) named Dizal Pharmaceutical.”

Vanc Pharmaceuticals has raised C$0.72m ($0.56m) through a non-brokered private placement of 4.85 million units priced at C$0.15 ($0.12m) a unit.

Each unit comprises one common share of the company and one transferrable share purchase warrant, which entitles the holder to purchase one additional common share at a price of C$0.2 ($0.16) a share.

The exercise date of the warrants will expire on 27 November 2022.

Based in Canada, Vanc manufactures and distributes generic and over-the-counter (OTC) pharmaceuticals.

The company will use the funds for operational and corporate expenses, as well as close technology acquisitions.

Hemispherx Biopharma plans to raise $1.59m through a public offering of shares of its common stock.

The US-based biopharmaceutical company has appointed Maxim Group as its underwriter and Silverman Shin & Byrne as its legal advisor for the funding round.

The funds are intended to be used towards working capital and general and administrative purposes.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now